464 related articles for article (PubMed ID: 27109926)
21. Targeting fibroblast growth factor receptor pathway in breast cancer.
Criscitiello C; Esposito A; De Placido S; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):452-6. PubMed ID: 26397764
[TBL] [Abstract][Full Text] [Related]
22. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.
Dieci MV; Arnedos M; Andre F; Soria JC
Cancer Discov; 2013 Mar; 3(3):264-79. PubMed ID: 23418312
[TBL] [Abstract][Full Text] [Related]
24. Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Vanni I; Boccardo S; Alama A; Grossi F
Expert Opin Investig Drugs; 2017 May; 26(5):551-561. PubMed ID: 28388262
[TBL] [Abstract][Full Text] [Related]
25. FGFR-targeted therapeutics for the treatment of breast cancer.
De Luca A; Frezzetti D; Gallo M; Normanno N
Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
[TBL] [Abstract][Full Text] [Related]
26. Small molecule inhibition of fibroblast growth factor receptors in cancer.
Liang G; Chen G; Wei X; Zhao Y; Li X
Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
[TBL] [Abstract][Full Text] [Related]
27. Recent advances of dual FGFR inhibitors as a novel therapy for cancer.
Liang Q; Wang J; Zhao L; Hou J; Hu Y; Shi J
Eur J Med Chem; 2021 Mar; 214():113205. PubMed ID: 33556787
[TBL] [Abstract][Full Text] [Related]
28. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
Chandana SR; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2020 Dec; 29(12):1413-1429. PubMed ID: 33074030
[TBL] [Abstract][Full Text] [Related]
29. Non-canonical fibroblast growth factor signalling in angiogenesis.
Murakami M; Elfenbein A; Simons M
Cardiovasc Res; 2008 May; 78(2):223-31. PubMed ID: 18056763
[TBL] [Abstract][Full Text] [Related]
30. FGFR signalling in women's cancers.
Fearon AE; Gould CR; Grose RP
Int J Biochem Cell Biol; 2013 Dec; 45(12):2832-42. PubMed ID: 24148254
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
32. FGFR-TKI resistance in cancer: current status and perspectives.
Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor receptors, developmental corruption and malignant disease.
Kelleher FC; O'Sullivan H; Smyth E; McDermott R; Viterbo A
Carcinogenesis; 2013 Oct; 34(10):2198-205. PubMed ID: 23880303
[TBL] [Abstract][Full Text] [Related]
34. [FGF/FGFR signalling: Implication in oncogenesis and perspectives].
Flippot R; Kone M; Magné N; Vignot S
Bull Cancer; 2015 Jun; 102(6):516-26. PubMed ID: 25986739
[TBL] [Abstract][Full Text] [Related]
35. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.
Squires M; Ward G; Saxty G; Berdini V; Cleasby A; King P; Angibaud P; Perera T; Fazal L; Ross D; Jones CG; Madin A; Benning RK; Vickerstaffe E; O'Brien A; Frederickson M; Reader M; Hamlett C; Batey MA; Rich S; Carr M; Miller D; Feltell R; Thiru A; Bethell S; Devine LA; Graham BL; Pike A; Cosme J; Lewis EJ; Freyne E; Lyons J; Irving J; Murray C; Newell DR; Thompson NT
Mol Cancer Ther; 2011 Sep; 10(9):1542-52. PubMed ID: 21764904
[TBL] [Abstract][Full Text] [Related]
36. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
Bello E; Colella G; Scarlato V; Oliva P; Berndt A; Valbusa G; Serra SC; D'Incalci M; Cavalletti E; Giavazzi R; Damia G; Camboni G
Cancer Res; 2011 Feb; 71(4):1396-405. PubMed ID: 21212416
[TBL] [Abstract][Full Text] [Related]
37. Dysregulated FGF signalling in neoplastic disorders.
Tanner Y; Grose RP
Semin Cell Dev Biol; 2016 May; 53():126-35. PubMed ID: 26463732
[TBL] [Abstract][Full Text] [Related]
38. Exploitation of phage display for the development of anti-cancer agents targeting fibroblast growth factor signaling pathways: New strategies to tackle an old challenge.
Jafari B; Hamzeh-Mivehroud M; Morris MB; Dastmalchi S
Cytokine Growth Factor Rev; 2019 Apr; 46():54-65. PubMed ID: 30898440
[TBL] [Abstract][Full Text] [Related]
39. Anticancer molecules targeting fibroblast growth factor receptors.
Liang G; Liu Z; Wu J; Cai Y; Li X
Trends Pharmacol Sci; 2012 Oct; 33(10):531-41. PubMed ID: 22884522
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor receptor inhibitors: patent review (2015-2019).
Marseglia G; Lodola A; Mor M; Castelli R
Expert Opin Ther Pat; 2019 Dec; 29(12):965-977. PubMed ID: 31679402
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
